We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
- Authors
Kim, H. -P.; Han, S. -W.; Song, S. -H.; Jeong, E. -G.; Lee, M. -Y.; Hwang, D.; Im, S. -A.; Bang, Y. -J.; Kim, T. -Y.
- Abstract
Human epidermal growth factor receptor 2 (HER2)-directed treatment using trastuzumab has shown clinical benefit in HER2-positive gastric cancer. Clinical trials using lapatinib in HER2-positive gastric cancer are also currently underway. As with other molecularly targeted agents, the emergence of acquired resistance to HER2-directed treatment is an imminent therapeutic problem for HER2-positive gastric cancer. In order to investigate the mechanisms of acquired resistance to HER2-directed treatment in gastric cancer, we generated lapatinib-reslstant gastric cancer cell lines (SNU216 LR) in vitro by chronic exposure of a HER2-positive gastric cancer cell line (SNU216) to lapatinib. The resultant SNU216 LR cells were also resistant to gefitinib, cetuximab, trastuzumab, afatinlb and dacomitinib. Interestingly, SNU216 LR cells displayed an epithelial-mesenchymal transition (EMT) phenotype and maintained the activation of MET, HER3, Stat3, Akt and mitogen-activated protein kinase signaling in the presence of lapatinib. Using gene expression arrays, we identified the upregulation of a variety of EMT-related genes and extracellular matrix molecules, such as Testican-1, in SNU216 LR cells. We showed that the Inhibition of Testican-1 by small interfering RNA decreased Testican-1-induced, MET-dependent, downstream signaling, and restored sensitivity to lapatinib in these cells. Furthermore, treatment with XAV939 selectively inhibited β-catenin-mediated transcription and Testican-1-induced EMT signaling, leading to Gl arrest. Taken together, these data support the potential role of EMT in acquired resistance to HER2-directed treatment in HER2-positive gastric cancer, and provide insights into strategies for preventing and/or overcoming this resistance in patients.
- Subjects
STOMACH cancer treatment; EPITHELIAL cells; MESENCHYMAL stem cells; EPIDERMAL growth factor receptor genetics; CELLULAR signal transduction; LAPATINIB; CLINICAL trials; CANCER cell culture
- Publication
Oncogene, 2014, Vol 33, Issue 25, p3334
- ISSN
0950-9232
- Publication type
Article
- DOI
10.1038/onc.2013.285